Skip to main content
Premium Trial:

Request an Annual Quote

InforMax Adds Shared-Database Option to Vector Suite

NEW YORK, Oct 12 – Bioinformatics software provider InforMax said Thursday that it has added a shared-database option to its Vector NTI Suite 6.0 of desktop applications for genomic and proteomic research.

Vector NTI Enterprise, as the new option is called, incorporates a shared Oracle database into a network of Vector NTI Suite applications designed to enable real-time collaboration among multiple researchers in a secure environment.

Data can be transferred freely between the desktop database and the shared database and viewed with a database explorer. The new shared database can save all types of data found in the Vector NTI Suite desktop database, as well as new types such as BLAST results and ENTREZ searches.

The Rockville, Md.-based company had also recently released version 3.0 of GenoMax—a software package that includes modules for sequence analysis, gene expression analysis, and 3-dimensional protein structure—for use in a multi-user environment.

Now vector users also have a shared-database option.

“For Vector users, Vector NTI Enterprise makes it easy for multiple researchers to share and access a wide variety of data types in a straightforward manner,” said Alex Titomirov, InforMax president and CEO, in a statement. " Researchers seeking to unlock the value of genomic and proteomic information must be able to collaborate on a real-time basis to optimize creativity and arrive at the desired research objective as quickly as possible,” he said.

The Vector NTI Suite consists of four major application programs, including the Vector NTI for mapping and illustration, primer design and analysis, and strategic recombinant design; BioPlot for protein and nucleic acid sequence analysis; AlignX for multiple sequence alignment; ContigExpress for sequencing project management and fragment assembly; and 3D-Mol for structure analysis and visualization.

InforMax raised $80 million earlier this month in an offering of five million shares.

The company reported revenues of $3.2 million in first-quarter 2000, up from $1.6 million in the year ago period. Software sales accounted for $2.4 million of this year’s first-quarter sales.
The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.